Background As the level of consciousness decreases in the dying process, patients lose their ability to swallow and clear oral secretions. As air moves over the secretions, which have pooled in the oropharynx and bronchi, the resulting turbulence produces noisy ventilation with each breath, described as gurgling or rattling noises. While there is no evidence that patients find this ‘death rattle’ disturbing, the noises may be disturbing to the patient’s visitors and caregivers who may fear that the patient is choking to death. However, similar sounds may occur in patients who are not imminently dying, such as in those with brain injuries or in patients with various disorders leading to increased production or decreased clearance of secretions. Two sub-types of the death rattle have been proposed, although the significance regarding treatment has not been established: Type 1 = predominantly salivary secretions and Type 2 = predominantly bronchial secretions. Death rattle is a good predictor of near death; one study indicated the median time from onset of death rattle to death was 16 hours.
Non-Pharmacological Treatments
Pharmacological Treatments While there are no evidence-based guidelines, the standard of care is to use muscarinic receptor blockers (anti-cholinergic drugs). These include scopolamine, hyoscyamine, glycopyrrolate, and atropine. All of these agents can cause varying degrees of blurred vision, sedation, confusion, delirium, restlessness, hallucinations, palpitations, constipation, and urinary retention. The primary difference in these drugs is whether they are tertiary amines which cross the blood-brain barrier (scopolamine, atropine, hyoscyamine) or quaternary amines, which do not (glycopyrrolate). Drugs which cross the BBB are apt to cause CNS toxicity (sedation, delirium).
Drug |
Trade Name |
Route |
Starting Dose |
Onset |
scopolamine (hyoscine) hydrobromide |
Transderm Scop |
Patch |
One 1.5 mg patch |
~12 h (24 h to steady state) |
hyoscyamine |
Levsin |
PO , SL |
0.125 mg |
30 min |
glycopyrrolate |
Robinul |
PO |
1mg |
30 min |
glycopyrrolate |
Robinul |
SubQ, IV |
0.2 mg |
1 min |
atropine sulfate |
Atropine |
SubQ, IV |
0.1 mg |
1 min |
atropine sulfate |
multiple |
Sublingual |
1gtt (1% ophth. soln) |
30 min |
Pharmacological pearls
References
Fast Facts and Concepts are edited by Drew A. Rosielle MD, Palliative Care Center, Medical College of Wisconsin. For comments/questions write to: drosiell@mcw.edu. More information, as well as the complete set of Fast Facts, is available at EPERC: www.eperc.mcw.edu.
Copyright/Referencing Information : Users are free to download and distribute Fast Facts for educational purposes only. Bickel K, Arnold R. Fast Fact and Concept #109. Death Rattle and Oral Secretions, 2 nd Edition. April 2008. End-of-Life/Palliative Education Resource Center ( www.eperc.mcw.edu).
History: 1 st Edition originally published March 2004.
Disclaimer: Fast Facts provide educational information. This information is not medical advice. Health care providers should exercise their own independent clinical judgment. Some Fast Fact information cites the use of a product in dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.
Purpose: Instructional Aid, Self-Study Guide, Teaching
Audience(s)
|
Training: Fellows, 3rd/4th Year Medical Students, PGY1 (Interns), PGY2-6, Physicians in Practice |
|
Specialty: Anesthesiology, Emergency Medicine, Family Medicine, General Internal Medicine, Geriatrics, Hematology/Oncology, Neurology, OB/GYN, Ophthalmology, Pulmonary/Critical Care, Pediatrics, Psychiatry, Surgery |
|
Non-Physician: Nurses |
ACGME Competencies: Medical Knowledge, Patient Care
Keyword(s): Non pain symptoms & syndromes